The face of clinical trials is constantly hanging with more challenges for drug developers than ever. Two core themes define this, new and evolving technologies, and more difficult disease targets.

Drugs for these targets tend to be riskier to develop and more expensive to produce. With this in mind the “too hard to handle” seminar will address the complexities of moving these drugs through the supply chain safely and efficiently whilst reducing uncertainty and cost.

Join PCI, Penn Pharma and World Courier at 7.30am for a complimentary breakfast meeting.

The program includes:

How Hard is Hard?
Jerome Detreille • Senior Director, New Business Development • Penn Pharma
Examining the complexities of taking these ‘hard to handle’ molecules through the manufacturing process including; the changing pharmaceutical landscape and the molecules considered “potent”, The Occupational Exposure Limit (OEL) assessment of potency, the latest internationally recognised guidelines on the handling of potent molecules and the state of the art equipment that ensures adherence to best practice through contained processing.

Turning Challenge Into Opportunity
Tim Roberts • Associate Director, Clinical Services • PCI
As todays early phase drug compounds and chemical structures become reliant upon tringent storage, atmospherically and temperature controlled conditions, PCI looks at some of today’s complex packaging challenges including the challenges in monitoring or maintaining low humidity, Nitrogen flushing, the practical challenges of packaging in refrigerated environments as well as the complex logistics of packaging Controlled Substances.

Its a Small World
Sue Lee • Technical Portfolio Manager • World Courier
At a time when supply chain integrity is receiving unprecedented interest from regulatory authorities World Courier considers the implications of a truly global supply chain, accessing the emerging markets, handling dangerous goods and ensuring GXP compliance through risk assessment and effective temperature control.

REGISTER NOW